正大企业国际2023中期报告

CHIATAIENTERPRISESINTERNATIONALLIMITED 正大企业国际有限公司 IncorporatedinBermudawithmembers’limitedliability•StockCode:3839 于百慕大注册成立之成员有限责任公司•股份代号：3839 INTERIMREPORT2023中期报告 Contents 目录 2 ManagementDiscussionandAnalysis管理层讨论及分析 6 ReportonReviewofInterimFinancialReport中期财务报告之审阅报告 8 ConsolidatedStatementofComprehensiveIncome综合全面收益表 10 ConsolidatedStatementofFinancialPosition综合财务状况表 12 ConsolidatedStatementofChangesinEquity综合权益变动表 14 CondensedConsolidatedStatementofCashFlows简明综合现金流量表 15 NotestoInterimFinancialReport中期财务报告附注 31 OtherInformation其他资料 35 CorporateInformation公司资料 MANAGEMENTDISCUSSIONANDANALYSIS 管理层讨论及分析 GROUPRESULTS TheGrouphastwolinesofbusiness:biochemicalbusinessandindustrialbusiness.Thebiochemicalbusinessfocusesonchlortetracycline(“CTC”)andotherrelatedproducts,andis 集团业绩 本集团从事生化业务及工业业务。生化业务专注于金霉素及其他相关产品，并由本集团之附属公司营运，乃占本集团的所有综合收入。工业业务包含本集团于ECI carriedonbyGroupsubsidiaries.Thisbusinesssegmentaccounts MetroInvestmentCo.,Ltd（. 及其附属公司，统称“ECI foralloftheGroup’sconsolidatedrevenue.TheindustrialbusinesscomprisestheGroup’sinterestsinitsjointventureECIMetroInvestmentCo.,Ltd.(togetherwithitssubsidiaries,“ECIMetro”)anditsassociateZhanjiangDeniVehiclePartsCo.,Ltd.(togetherwithitssubsidiaries,“ZhanjiangDeni”).TheresultsoftheGroup’sindustrialbusinessareincorporatedintheconsolidatedstatementofcomprehensiveincomeasshareofprofitsandlossesofjointventureandassociate. Forthesixmonthsended30June2023(“1H23”),theGroup’srevenueincreasedby2.0%toUS$82.81million.Forthesixmonthsended30June2022(“1H22”),theGroup’srevenuewasUS$81.21million.Overallgrossprofitmarginwasat22.3%(1H22:23.6%). ProfitattributabletoshareholdersoftheCompanywasUS$2.03million(1H22:lossofUS$4.98million).Theturnfromlosstoprofitwasmainlyduetoimprovedperformanceofourindustrialbusiness.ShareofprofitsandlossesofECIMetroimprovedfromalossofUS$5.34millionin1H22toaprofitofUS$2.61millionin1H23. Basicanddilutedprofitpersharewereboth0.80UScents(1H2022:lossof1.97UScents).TheboardofdirectorsoftheCompanyresolvednottodeclareaninterimdividendforthesixmonthsended30June2023(1H22:Nil). BUSINESSREVIEW Biochemical WegenerateasizableportionofourrevenuefromthemanufactureandsaleofCTCproducts(CTCPremixandCTCHCL)andanimalhealthproducts.CTCproductsareantibioticsusedtopreventorcureanimaldiseases.Whileouranimalhealthproductsaremainlypreventivedrugsforlivestockdiseases.Inthepastfewyears,wehavebeenstrategicallybroadeningourproductportfoliotocoverotherrelatedveterinaryproducts.Ofthesenewofferings,somewemanufactureandsale,andsomewesourceandtrade.TheGroup’smajorcustomersincludefarms,pharmaceuticalcompanies,tradingcompaniesandfeedmills. Metro”）的合营企业权益及于湛江德利车辆部件有限公司（及其附属公司，统称“湛江德利”）的联营公司权益。本集团工业业务的业绩载列于综合全面收益表内的应占合营企业及联营公司溢利及亏损。 截至二零二三年六月三十日止六个月（“二零二三年上半年”），本集团的收入上升2.0%至8,281万美元。截至二零二二年六月三十日止六个月（“二零二二年上半年”），本集团的收入为8,121万美元。整体毛利率为22.3%（二零二二年上半年：23.6%）。 本公司股东应占溢利为203万美元（二零二二年上半年：亏损498万美元）。由亏转盈主要由于工业业务表现有改善，应占ECIMetro溢利及亏损从二零二二年上半年亏损534万美元改善至二零二三年上半年盈利261万美元。 每股基本及摊薄溢利为0.80美仙（二零二二年上半年：亏损1.97美仙）。本公司董事会决议截至二零二三年六月三十日止六个月不派付中期股息（二零二二年上半年：无）。 业务回顾 生化业务 我们的收入大部分来自制造及销售金霉素产品（金霉素预混剂及盐酸金霉素）和动保化药产品。金霉素产品为用作预防或治疗动物疾病的抗生素。而我们的动保化药产品主要是用作家畜疾病的防治药。近年，我们一直在战略性地扩大我们的产品组合，以涵盖其他相关的兽药产品。在这些新产品中，一部分我们制造及销售，一部分我们采购和贸易。本集团的主要客户包括养殖场、制药公司、贸易公司及饲料加工厂。 In1H23,theGroup’srevenuefromthebiochemicalbusinessamountedtoUS$82.81million(1H22:US$81.21million).Whilesalesremainedstable,oursalesmixchangedinlinewithourstrategicbusinessdirection.RevenuecontributionfromCTCproductsdecreasedfrom57%in1H22to48%in1H23,whilerevenuecontributionfromanimalhealthproducts,tradingandothersegmentsincreasedfrom43%in1H22to52%in1H23.Grossprofitmarginin1H23was22.3%(1H22:23.6%). DuetoreducedCTCproductdemandin1H23,ourfactoryutilisationratedropped,increasingourproductionoverheadinthisperiod.Again,inlinewithourstrategicbusinessdirection,wecontinuedtodeployadditionalmarketingeffortstoexpandouranimalhealthandtradingbusinesses.Overall,contributionfromourbiochemicalbusinessdeclinedin1H23. Industrial TheGroup’sindustrialbusinessisconductedthroughECIMetroandZhanjiangDeni. ECIMetroisprincipallyengagedinthesale,leasingandservicingofCaterpillarmachineryequipmentinwesternChina.TheexcavatormarketinChinahadbeenimpactedbyadeclineinconstructionmachinerydemandsince2022.AccordingtotheChinaConstructionMachineryAssociation,excavatorsalesacrosstheentiremarketin1H2023was43.8%lowerthanthatin1H2022.Ourmarketshareinthesmallandmedium-sizedconstructionmachinerysegmentwasalsocontinuouslychallengedbydomesticbrandsinChina.Nevertheless,revenueandgrossprofitfromsalesofsparepartsandservicesincreasedduetorisingdemand.Furthermore,machinerywithnewemissionstandardshadbettergrossprofitmargin.Asaresult,forthesixmonthsended30June2023,ourshareofprofitsandlossesofjointventureimprovedfromalossofUS$5.34millionin1H22toaprofitofUS$2.61millionin1H23. ZhanjiangDeniisprincipallyengagedinthemanufactureandsaleofautomotiveparts,whicharemainlysoldtoautomobileandmotorcyclemanufacturers.AccordingtotheChinaAssociationofAutomobileManufacturers,automobilesalesin1H2023increasedby9.8%whencomparedto1H2022.On